Underwriting AgreementUnderwriting Agreement • February 24th, 2014 • Lilly Eli & Co • Pharmaceutical preparations • New York
Eli Lilly and Company, an Indiana corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), $600,000,000 principal amount of its 1.950% Notes due 2019 (the “2019 Notes”) and $400,000,000 principal amount of its 4.650% Notes due 2044 (the “2044 Notes”), in each case having the terms set forth in Schedule 2 hereto (such 2019 Notes and 2044 Notes collectively, the “Securities”). The Securities will be issued pursuant to an Indenture dated as of February 1, 1991 (as may be supplemented from time to time, the “Indenture”) between the Company and Deutsche Bank Trust Company Americas, a New York banking corporation (as successor to Citibank, N.A., the original trustee), as trustee (the “Trustee”).
